These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12552068)

  • 1. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.
    Pijnenburg YA; Schoonenboom NS; Scheltens P
    Neurology; 2003 Jan; 60(2):353-4; author reply 353-4. PubMed ID: 12552068
    [No Abstract]   [Full Text] [Related]  

  • 2. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.
    Schoonenboom NS; Pijnenburg YA; Mulder C; Rosso SM; Van Elk EJ; Van Kamp GJ; Van Swieten JC; Scheltens P
    Neurology; 2004 May; 62(9):1580-4. PubMed ID: 15136685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.
    Riemenschneider M; Wagenpfeil S; Diehl J; Lautenschlager N; Theml T; Heldmann B; Drzezga A; Jahn T; Förstl H; Kurz A
    Neurology; 2002 Jun; 58(11):1622-8. PubMed ID: 12058089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration.
    Pijnenburg YA; Schoonenboom NS; Rosso SM; Mulder C; Van Kamp GJ; Van Swieten JC; Scheltens P
    Neurology; 2004 May; 62(9):1649. PubMed ID: 15136709
    [No Abstract]   [Full Text] [Related]  

  • 6. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
    Kapaki E; Paraskevas GP; Zalonis I; Zournas C
    Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M; Andreasen N; Blennow K
    Clin Chim Acta; 2003 Jun; 332(1-2):1-10. PubMed ID: 12763273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comments on the article by K. Buch et al. Tau protein: a potential biological marker for early detection of Alzheimer disease. Nervenarzt (1998) 69:379-385].
    Otto M; Wiltfang J; Poser S; Kornhuber J
    Nervenarzt; 1999 Jul; 70(7):668-70. PubMed ID: 10434268
    [No Abstract]   [Full Text] [Related]  

  • 10. No added diagnostic value of non-phosphorylated tau fraction (p-tau
    Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers in frontotemporal lobar degeneration with known pathology.
    Bian H; Van Swieten JC; Leight S; Massimo L; Wood E; Forman M; Moore P; de Koning I; Clark CM; Rosso S; Trojanowski J; Lee VM; Grossman M
    Neurology; 2008 May; 70(19 Pt 2):1827-35. PubMed ID: 18458217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings.
    Tolboom N; Koedam EL; Schott JM; Yaqub M; Blankenstein MA; Barkhof F; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimer Dis Assoc Disord; 2010; 24(3):303-7. PubMed ID: 20683187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.
    Kanemaru K; Kameda N; Yamanouchi H
    Neurology; 2000 May; 54(9):1875-6. PubMed ID: 10802808
    [No Abstract]   [Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
    Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging.
    Pijnenburg YA; Schoonenboom SN; Barkhof F; Knol DL; Mulder C; Van Kamp GJ; Van Swieten JC; Scheltens P
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):246-8. PubMed ID: 16421130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.
    Bruzova M; Rusina R; Stejskalova Z; Matej R
    Sci Rep; 2021 May; 11(1):10837. PubMed ID: 34035398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.